SCHEMBL206947

SCHEMBL206947

NC(=O)[N]c1ccccn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 4/20 0.59
ADRA2B P18089 4/20 0.59
ADRA2C P18825 4/20 0.59
PLAU P00749 1/20 0.59
NOS3 P29474 2/20 0.46
NOS1 P29475 2/20 0.46
NOS2 P35228 2/20 0.46
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
LMNA P02545 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
PKM P14618 2/20 0.40
MITF O75030 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851528 0.81 ADRA2A (0.50) ADRA2AADRA2BADRA2CPLAUNOS3
SCHEMBL10841156 0.79 ALDH1A1 (0.50) ADRA2AADRA2BADRA2CPLAUNOS3
SCHEMBL10841472 0.76 KMT2A (0.48) ADRA2AADRA2BADRA2CPLAUMAOA
SCHEMBL3536341 0.75 ADRA2A (0.44) ADRA2AADRA2BADRA2CPLAUNOS3
SCHEMBL2215019 0.75 NOS3 (0.46) ADRA2AADRA2BADRA2CPLAUNOS3
SCHEMBL2226462 0.74 ADRA2A (1.00) ADRA2AADRA2BADRA2CPLAUNOS3
SCHEMBL5970257 0.73 ADRA2A (0.43) ADRA2AADRA2BADRA2CPLAUMAOA
SCHEMBL6156050 0.73 CES2 (0.39) ADRA2AADRA2BADRA2CPLAUCES2
SCHEMBL4021935 0.71 ADRA2A (0.70) ADRA2AADRA2BADRA2CPLAUNOS3
SCHEMBL1703431 0.71 ADRA2A (0.70) ADRA2AADRA2BADRA2CPLAUNOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2009-06-25 US claimed
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production DR. KARL THOMAE GMBH (DE) 2004-10-28 US claimed
EP-1440976-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-07-28 EP claimed
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2003-04-10 US claimed
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production RUDOLF KLAUS (DE) 2001-11-01 US claimed
CN-113241478-A Electrolyte solution, electrochemical device, and electricity-consuming apparatus 宁德新能源科技有限公司 2021-08-10 CN disclosed
US-9988373-B2 Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2018-06-05 US disclosed
US-9882072-B2 Solar cell and transparent electrode Konica Minolta, Inc. (JP) 2018-01-30 US disclosed
EP-3093898-A1 ORGANIC ELECTROLUMINESCENCE DEVICE, LIGHTING DEVICE AND DISPLAY DEVICE Konica Minolta Holdings, Inc. (JP) 2016-11-16 EP disclosed
EP-2001065-B1 ORGANIC ELECTROLUMINESCENT DEVICE, ILLUMINATING DEVICE AND DISPLAY DEVICE KONICA MINOLTA HOLDINGS INC (JP) 2016-11-09 EP disclosed
US-20160318916-A1 NITROGEN-CONTAINING SIX-MEMBERED CYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2016-11-03 US disclosed
US-9202636-B2 Photoelectric conversion element and dye-sensitized solar cell KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) 2015-12-01 US disclosed
EP-1136877-A2 Photothermographic material KONICA CORPORATION (JP) 2001-09-26 EP disclosed
US-5891614-A FORMING HALOGEN COMPOSITION GAP FACES AT TIME OF NUCLEATION TO PRODUCE TABULAR GRAINS FUJI PHOTO FILM CO., LTD. (JP) 1999-04-06 US disclosed
US-5780209-A Processing of photographic silver halide photosensitive material FUJI PHOTO FILM CO., LTD. (JP) 1998-07-14 US disclosed
US-5667960-A VINYL SULFONE DERIVATIVES KONICA CORPORATION (JP) 1997-09-16 US disclosed
EP-0752615-A2 Method for hardening gelatin and silver halide photographic light sensitive materials employing the method KONICA CORPORATION (JP) 1997-01-08 EP disclosed
US-5582962-A COLLOID LAYERS COMPRISING A DISPERSE DYE PARTICLES KONICA CORPORATION (JP) 1996-12-10 US disclosed
EP-0679935-A2 Silver halide photographic light-sensitive material and the processing method thereof KONICA CORPORATION (JP) 1995-11-02 EP disclosed
US-5120637-A Storage stability FUJI PHOTO FILM CO., LTD. (JP) 1992-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163480-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, CHRM1, SRMS ADRA2A 137/4885ADRA2B 157/4885ADRA2C 169/4885
US-20160318916-A1 NITROGEN-CONTAINING SIX-MEMBERED CYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NGLY1, C1R ADRA2A 1139/4885ADRA2B 850/4885ADRA2C 353/4885
US-20040214819-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 ADRA2A 66/4885ADRA2B 106/4885ADRA2C 76/4885
US-20030069231-A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production SLC1A5, NEFM, SRMS ADRA2A 70/4885ADRA2B 78/4885ADRA2C 69/4885
US-20010036946-A1 Modified amino acids, pharmaceuticals containing these compounds and method for their production PTMS, SRMS, OPRM1 ADRA2A 66/4885ADRA2B 106/4885ADRA2C 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.